Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
Harry Kleanthous, Judith M. Silverman, Karen W. Makar, et al.
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 138

Showing 1-25 of 138 citing articles:

Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults
Lianpan Dai, Lidong Gao, Lifeng Tao, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 22, pp. 2097-2111
Open Access | Times Cited: 228
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
Alexander A. Cohen, Neeltje van Doremalen, Allison J. Greaney, et al.
Science (2022) Vol. 377, Iss. 6606
Open Access | Times Cited: 199
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial
Joon Young Song, Won Suk Choi, Jung Yeon Heo, et al.
EClinicalMedicine (2022) Vol. 51, pp. 101569-101569
Open Access | Times Cited: 85
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
Fatemeh Bayani, Negin Safaei Hashkavaei, Sareh Arjmand, et al.
Progress in Biophysics and Molecular Biology (2023) Vol. 178, pp. 32-49
Open Access | Times Cited: 49
ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
Magnus A. G. Hoffmann, Zhi Yang, Kathryn E. Huey‐Tubman, et al.
Cell (2023) Vol. 186, Iss. 11, pp. 2380-2391.e9
Open Access | Times Cited: 46
Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds
Eike‐Christian Wamhoff, Larance Ronsard, Jared Feldman, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 42
A large-scale database of T-cell receptor beta sequences and binding associations from natural and synthetic exposure to SARS-CoV-2
Sean Nolan, Marissa Vignali, Mark Klinger, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 3
DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response
Esra Oktay, Farhang Alem, Keziah Hernandez, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 32
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
Júlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
The Lancet Regional Health - Europe (2023) Vol. 28, pp. 100613-100613
Open Access | Times Cited: 26
Incidence and management of the main serious adverse events reported after COVID‐19 vaccination
Teresa Padilla‐Flores, Alicia Sampieri, Luis Vaca
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 3
Open Access | Times Cited: 9
Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2
Yu Liang, Jing Zhang, Run Yu Yuan, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 31
A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
Shixia Wang, Chang Yi Wang, Hui-Kai Kuo, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 2724-2734
Open Access | Times Cited: 31
An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission
Kairat Tabynov, Nurkeldi Turebekov, Meruert Babayeva, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 30
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2
Antonio Barreiro, Antoni Prenafeta, G. Bech-Sàbat, et al.
iScience (2023) Vol. 26, Iss. 3, pp. 106126-106126
Open Access | Times Cited: 22
Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines
Xiao‐Qing Guan, Yang Yang, Lanying Du
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 422-439
Open Access | Times Cited: 20
Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants
Isabelle Montgomerie, Thomas W. Bird, Olga R. Palmer, et al.
iScience (2023) Vol. 26, Iss. 4, pp. 106256-106256
Open Access | Times Cited: 17
Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
Alexander A. Cohen, Jennifer R. Keeffe, Ariën Schiepers, et al.
Cell (2024) Vol. 187, Iss. 20, pp. 5554-5571.e19
Open Access | Times Cited: 7
Advanced Materials for SARS‐CoV‐2 Vaccines
Moustafa T. Mabrouk, Wei‐Chiao Huang, Luis Martínez‐Sobrido, et al.
Advanced Materials (2021) Vol. 34, Iss. 12
Open Access | Times Cited: 37
The rapid progress in COVID vaccine development and implementation
Alan D.T. Barrett, Richard W. Titball, Paul A. MacAry, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 28
Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine
Jonathan F. Lovell, Yeong Ok Baik, Seuk Keun Choi, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 26
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster
Farshad Guirakhoo, Shixia Wang, Chang Yi Wang, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 8, pp. 1401-1406
Open Access | Times Cited: 23
Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2
Michael D. Grant, Kirsten Bentley, Ceri A. Fielding, et al.
JCI Insight (2023) Vol. 8, Iss. 15
Open Access | Times Cited: 15
Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
Alexander A. Cohen, Jennifer R. Keeffe, Ariën Schiepers, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
CHO cells for virus-like particle and subunit vaccine manufacturing
Zalma V. Sanchez-Martinez, Sergio P. Alpuche-Lazcano, Matthew Stuible, et al.
Vaccine (2024) Vol. 42, Iss. 10, pp. 2530-2542
Open Access | Times Cited: 6
Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines
Jie Zhou, Zezhong Liu, Guangxu Zhang, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top